GSK Price to Free Cash Flow Ratio 2010-2024 | GSK

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

GSK average price to free cash flow ratio for 2024 was 10.56, a 22.18% decline from 2023.
GSK average price to free cash flow ratio for 2023 was 13.57, a 84.12% decline from 2022.
GSK average price to free cash flow ratio for 2022 was 7.37, a 27.46% increase from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

GSK average price to free cash flow ratio for 2024 was 10.56, a 22.18% decline from 2023.
GSK average price to free cash flow ratio for 2023 was 13.57, a 84.12% decline from 2022.
GSK average price to free cash flow ratio for 2022 was 7.37, a 27.46% increase from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$151.4B
Bristol Myers Squibb (BMY)	$119.8B
Gilead Sciences (GILD)	$119.1B
Vertex Pharmaceuticals (VRTX)	$113.7B
CSL (CSLLY)	$83.5B
Regeneron Pharmaceuticals (REGN)	$75.5B
Argenex SE (ARGX)	$39.5B
Alnylam Pharmaceuticals (ALNY)	$35.3B
BioNTech SE (BNTX)	$29B
BeiGene (ONC)	$22.2B
Biogen (BIIB)	$21B
Illumina (ILMN)	$20.9B
Moderna (MRNA)	$15.7B
Incyte (INCY)	$14.2B
Insmed (INSM)	$14B
Intra-Cellular Therapies (ITCI)	$13.5B
Genmab (GMAB)	$13.1B
Genmab (GNMSF)	$12.9B
BioMarin Pharmaceutical (BMRN)	$12.1B
Bio-Techne Corp (TECH)	$11.4B
Vaxcyte (PCVX)	$11.1B
Sarepta Therapeutics (SRPT)	$11B
Exact Sciences (EXAS)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Bio-Rad Laboratories (BIO.B)	$10B
QIAGEN (QGEN)	$9.7B
Repligen (RGEN)	$9.5B
Exelixis (EXEL)	$9.4B
Roivant Sciences (ROIV)	$8.1B
Ascendis Pharma (ASND)	$7.7B